More about

Type 2 Diabetes

News
November 15, 2022
3 min read
Save

Sotagliflozin reduces 30-day HF readmission rates in type 2 diabetes

Sotagliflozin reduces 30-day HF readmission rates in type 2 diabetes

CHICAGO — The dual SGLT inhibitor sotagliflozin reduced 30- and 90-day rates of CV mortality and HF-related events when administered before hospital discharge after an episode of worsening HF, according to new data from the SOLOIST trial.

News
November 15, 2022
1 min read
Save

Nighttime outdoor artificial light may increase type 2 diabetes risk

Nighttime outdoor artificial light may increase type 2 diabetes risk

Chronic exposure to outdoor artificial light at night was associated with increased glucose levels, HbA1c and insulin resistance, according to study findings published in Diabetologia.

News
November 14, 2022
1 min read
Save

Obesity plus low muscle mass may increase CKD risk in type 2 diabetes

Obesity plus low muscle mass may increase CKD risk in type 2 diabetes

Sarcopenic obesity may increase the risk for chronic kidney disease among adults with type 2 diabetes, but low muscle mass without obesity was not associated with CKD, according to study results published in Obesity.

News
November 10, 2022
4 min read
Save

Diabetes incidence higher among young people with vs. without Down syndrome

Diabetes incidence higher among young people with vs. without Down syndrome

Children, adolescents and young adults with Down syndrome have higher incidence rates of type 1 and type 2 diabetes compared with matched controls without Down syndrome, according to a study published in Diabetes Care.

News
November 09, 2022
1 min read
Save

Speaker: Isuzinaxib effective in patients with CKD, type 2 diabetes

Speaker: Isuzinaxib effective in patients with CKD, type 2 diabetes

ORLANDO — Isuzinaxib, a pan-NOX inhibitor modulating oxidative stress by Aptabio significantly reduced urine albumin-to-creatinine ratio in patients with type 2 diabetes and chronic kidney disease, according to data at ASN Kidney Week.

News
November 05, 2022
3 min read
Save

Pemafibrate lowers triglycerides but not CV events in type 2 diabetes, mixed dyslipidemia

Pemafibrate lowers triglycerides but not CV events in type 2 diabetes, mixed dyslipidemia

CHICAGO — In the PROMINENT trial, pemafibrate lowered triglycerides but did not cut the incidence of CV events compared with placebo in patients with type 2 diabetes and mixed dyslipidemia.

News
November 04, 2022
2 min read
Save

Glucagon/GLP-1 dual receptor agonist bests 1 mg semaglutide for weight loss: Phase 2 trial

Glucagon/GLP-1 dual receptor agonist bests 1 mg semaglutide for weight loss: Phase 2 trial

SAN DIEGO — A weekly glucagon/GLP-1 dual receptor agonist conferred greater weight loss than 1 mg semaglutide at 16 weeks among adults with type 2 diabetes, according to findings from a phase 2 trial.

News
November 04, 2022
2 min read
Save

Virtual diabetes-tailored weight management program benefits adults with type 2 diabetes

Virtual diabetes-tailored weight management program benefits adults with type 2 diabetes

SAN DIEGO — A virtual diabetes-tailored weight management program resulted in beneficial and clinically meaningful effects on glucose levels, body weight and diabetes distress among adults with type 2 diabetes.

News
October 31, 2022
2 min read
Save

Mindfulness, yoga ‘as strong as drug therapy’ plus lifestyle intervention in type 2 diabetes

Mindfulness, yoga ‘as strong as drug therapy’ plus lifestyle intervention in type 2 diabetes

Mind- and body-based practices, including mindfulness-based stress reduction, qigong and yoga, are associated with a reduction in HbA1c for adults with type 2 diabetes, according to findings from a systematic review and meta-analysis.

News
October 27, 2022
1 min read
Save

Healio releases Clinical Guidance, a point-of-care resource for providers

Healio releases Clinical Guidance, a point-of-care resource for providers

Healio has launched a new point-of-care tool with modules on medical conditions to help clinicians treat patients using reliable information.

View more